Huahai Pharmaceutical: Subsidiary Reaches Global Research Collaboration and Licensing Agreement with ALM

MetaMuskRat · 2026-03-28T13:51:24+00:00

Huahai Pharmaceutical announced that its subsidiary Huaao Tai has reached a global research collaboration agreement with Almirall to jointly develop monoclonal antibody drugs targeting new targets. Huaao Tai is responsible for the Chinese market, while ALM handles the global market. The agreement involves funding support of up to $340 million.

MetaMuskRat

2026-03-28 13:51:24

Abstract generation in progress

On March 27, People’s Financial News reported that Huahai Pharmaceutical (600521) announced on March 27 that its subsidiary Shanghai Huao Tai Biopharmaceutical Co., Ltd. (referred to as “Huao Tai”) has reached a global research collaboration and licensing agreement with Almirall, S.A. (referred to as “ALM”) for the development of a monoclonal antibody candidate drug targeting new targets with multiple potential indications, including medical dermatology. According to the agreement, Huao Tai has the rights to develop and commercialize the project and products in China, while ALM has the rights to develop and commercialize the project and products outside of China. Utilizing its innovative R&D platform, Huao Tai will conduct related research until obtaining a molecular candidate with clinical proof of concept, and ALM will pay Huao Tai a total of up to $340 million in upfront payments, development and commercialization milestone payments, as well as corresponding tiered royalties.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.